BR112012026403A2 - - Google Patents
Info
- Publication number
- BR112012026403A2 BR112012026403A2 BR112012026403A BR112012026403A BR112012026403A2 BR 112012026403 A2 BR112012026403 A2 BR 112012026403A2 BR 112012026403 A BR112012026403 A BR 112012026403A BR 112012026403 A BR112012026403 A BR 112012026403A BR 112012026403 A2 BR112012026403 A2 BR 112012026403A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32494410P | 2010-04-16 | 2010-04-16 | |
| US61/324,944 | 2010-04-16 | ||
| PCT/US2011/032641 WO2011130603A2 (en) | 2010-04-16 | 2011-04-15 | Anti-vla-4 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012026403A2 true BR112012026403A2 (US06818201-20041116-C00086.png) | 2017-09-05 |
| BR112012026403A8 BR112012026403A8 (pt) | 2018-01-02 |
| BR112012026403B1 BR112012026403B1 (pt) | 2022-10-04 |
Family
ID=44628095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012026403-6A BR112012026403B1 (pt) | 2010-04-16 | 2011-04-15 | Molécula de anticorpo recombinante ou um fragmento de ligação a ?4 da mesma e seu uso |
Country Status (24)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2558499T (lt) | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Antikūnai prieš vla-4 |
| CN105658667A (zh) * | 2013-07-05 | 2016-06-08 | 比奥根Ma公司 | 用于治疗中风的组合物和方法 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AR106184A1 (es) | 2015-09-29 | 2017-12-20 | Celgene Corp | Proteínas de unión a pd-1 y sus métodos de uso |
| KR102257154B1 (ko) | 2016-09-19 | 2021-05-28 | 셀진 코포레이션 | Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법 |
| WO2018053401A1 (en) * | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JP2019136398A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社三洋物産 | 遊技機 |
| JP2019136399A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社三洋物産 | 遊技機 |
| CN112867394A (zh) * | 2018-06-04 | 2021-05-28 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| WO2021234560A1 (en) | 2020-05-19 | 2021-11-25 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor |
| BR102020016890A2 (pt) | 2020-08-19 | 2022-05-03 | Fundação Oswaldo Cruz | Proteina, polinucleotídeo, vetor, célula hospedeira, composição, método para tratar uma doença, método in vitro para prognosticar esclerose múltipla, e, uso de uma proteína ou composição |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| KR20240008345A (ko) | 2021-05-18 | 2024-01-18 | 얀센 바이오테크 인코포레이티드 | T 세포 재유도 치료제 및 항-cd44 치료제를 포함하는 조성물 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| JPS6081397A (ja) | 1983-10-06 | 1985-05-09 | 荒川化学工業株式会社 | 中性抄紙方法 |
| US4494880A (en) | 1984-03-14 | 1985-01-22 | Su Wen Kuang | Foldable clock dial |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| SE461013B (sv) | 1988-02-11 | 1989-12-18 | Christian Wesslau | Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5217870A (en) | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
| US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
| US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| DK0626861T4 (da) | 1992-01-13 | 2004-08-16 | Biogen Inc | Behandling af astma. |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| ATE151642T1 (de) | 1992-02-12 | 1997-05-15 | Biogen Inc | Behandlung für entzündungserkrankung des darmes |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| CA2148712C (en) | 1992-11-13 | 2012-01-17 | Thalia Papayannopoulou | Peripheralization of hematopoietic stem cells |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| WO1994017818A1 (en) | 1993-02-08 | 1994-08-18 | The Syntex-Synergen Neuroscience Joint Venture | Methods for treating amyotrophic lateral sclerosis with cntf |
| DE69407758T3 (de) | 1993-02-09 | 2007-05-24 | Biogen Idec Ma Inc., Cambridge | Antikörper zur behandlung von insulinabhängigem diabetes |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6432404B1 (en) | 1993-12-23 | 2002-08-13 | Icos Corporation | Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies |
| EP0804237B8 (en) | 1994-01-25 | 2006-11-08 | Elan Pharmaceuticals, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5672622A (en) | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
| SE504751C2 (sv) | 1994-06-30 | 1997-04-21 | Lars Fredriksson | Kopplingslänk |
| US5498156A (en) | 1994-09-02 | 1996-03-12 | Ipsco Enterprises Inc. | Dual-purpose guide and drum cleaner for Steckel mill coiler furnace |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| HU228630B1 (en) | 1996-02-09 | 2013-04-29 | Abbott Biotech Ltd | Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity |
| KR100504449B1 (ko) | 1996-07-25 | 2005-07-29 | 바이오겐 아이덱 엠에이 인코포레이티드 | 세포 유착 억제제 |
| US7361331B2 (en) | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
| KR20010022413A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 벤질화합물 |
| US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
| JP2001527040A (ja) | 1997-12-30 | 2001-12-25 | バイオアブソーバブル コンセプツ，インコーポレイティド | 神経系の脳血管性疾患を治療、抑制及び防止するためのテトラサイクリン及び／又はテトラサイクリン誘導体 |
| IL139967A (en) | 1998-05-28 | 2005-11-20 | Biogen Idec Inc | Beta-alanine derivatives and pharmaceutical compositions containing the same |
| US7232830B2 (en) | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
| PT1113810E (pt) * | 1998-09-14 | 2009-03-10 | Univ Texas | Processos de tratamento de mieloma múltiplo e reabsorção óssea induzida por mieloma utilizando antagonistas da ligação do receptor de integrina |
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| JP2002538167A (ja) | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
| WO2001045725A2 (en) | 1999-12-23 | 2001-06-28 | Ancile Pharmaceuticals, Inc. | Treatment for inflammatory bowel disease (ibd) and related conditions |
| WO2001055112A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| EP1272506B1 (en) | 2000-03-31 | 2015-07-29 | The Scripps Research Institute | Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
| CA2487039A1 (en) | 2001-06-11 | 2002-12-19 | Transition Therapeutics Inc. | Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| CA2860702C (en) | 2001-12-17 | 2019-02-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| US20040203031A1 (en) | 2002-04-03 | 2004-10-14 | University Of Pennsylvania | Methods for determining drug responsiveness |
| KR20040084911A (ko) | 2002-02-15 | 2004-10-06 | 코넬 리서치 파운데이션 인코포레이티드 | 희소돌기아교세포 선조 세포를 이용한 선천적으로미엘린화되지 않은 전뇌의 미엘린화 |
| SI2336184T1 (sl) | 2002-02-25 | 2015-04-30 | Biogen Idec Ma Inc. | Dajanje sredstev za zdravljenje vnetij |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
| US20040141947A1 (en) | 2002-10-16 | 2004-07-22 | Hunter Samuel F. | Method for treatment of demyelinating central nervous system disease |
| ATE455853T1 (de) | 2002-11-22 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Antikörper gegen geschädigtes gewebe |
| CA2514125A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| JP4728948B2 (ja) | 2003-02-10 | 2011-07-20 | エラン ファーマシューティカルズ，インコーポレイテッド | 免疫グロブリン製剤およびその調製の方法 |
| US20050074443A1 (en) | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| US20050276803A1 (en) | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Method for augmenting B cell depletion |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| HUE058817T2 (hu) | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
| EP2808033A1 (en) | 2004-11-19 | 2014-12-03 | Biogen Idec MA Inc. | Treatment for multiple sclerosis |
| EP1833509A4 (en) * | 2004-12-03 | 2008-12-03 | Biogen Idec Inc | DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS |
| EP1869084A2 (en) | 2005-03-04 | 2007-12-26 | Biogen Idec MA Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| ATE496041T1 (de) | 2005-06-09 | 2011-02-15 | Ucb Pharma Sa | 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| DK2034830T3 (da) | 2006-05-25 | 2014-10-27 | Biogen Idec Inc | Anti-vla-1-antistof til behandling af slagtilfælde |
| EP2053961A4 (en) | 2006-08-09 | 2013-05-01 | Biogen Idec Inc | METHOD FOR DISPENSING A MEDICAMENT |
| US8771689B2 (en) | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
| US8931218B2 (en) | 2007-04-19 | 2015-01-13 | Oldcastle Building Products, Inc. | Modular brick or block outdoor structures |
| BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| DK2170390T3 (en) | 2007-06-14 | 2019-01-21 | Biogen Ma Inc | NATALIZUMABANTISTIC FORMULATIONS |
| WO2008157282A1 (en) | 2007-06-18 | 2008-12-24 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| DE102007049542A1 (de) | 2007-10-16 | 2009-04-23 | Neue Magnetodyn Gmbh | Implantierbare Vorrichtung, System zum Erzeugen lokalisierter elektromagnetischer Felder im Bereich eines Implantats und Spulenanordnung |
| EP2050462A1 (en) | 2007-10-18 | 2009-04-22 | PAION Deutschland GmbH | Improved treatment of stroke patients |
| LT2558499T (lt) * | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Antikūnai prieš vla-4 |
| BR112014009144A8 (pt) | 2011-10-17 | 2017-06-20 | Univ Muenster Westfaelische Wilhelms | avaliação do risco de pml e métodos com base na mesma |
-
2011
- 2011-04-15 LT LTEP11730120.0T patent/LT2558499T/lt unknown
- 2011-04-15 ME MEP-2020-168A patent/ME03813B/me unknown
- 2011-04-15 ES ES18205524T patent/ES2912934T3/es active Active
- 2011-04-15 SG SG2012071999A patent/SG184318A1/en unknown
- 2011-04-15 SI SI201131902T patent/SI3202789T1/sl unknown
- 2011-04-15 DK DK18205524.4T patent/DK3466977T3/da active
- 2011-04-15 PL PL11730120T patent/PL2558499T3/pl unknown
- 2011-04-15 EA EA201291065A patent/EA201291065A1/ru unknown
- 2011-04-15 EP EP21218415.4A patent/EP4032912A1/en active Pending
- 2011-04-15 SI SI201131238T patent/SI2558499T1/sl unknown
- 2011-04-15 CA CA2794863A patent/CA2794863C/en active Active
- 2011-04-15 SG SG10201502967RA patent/SG10201502967RA/en unknown
- 2011-04-15 EP EP17163411.6A patent/EP3202789B1/en active Active
- 2011-04-15 JP JP2013505169A patent/JP6085554B2/ja active Active
- 2011-04-15 ES ES17163411T patent/ES2805873T3/es active Active
- 2011-04-15 RS RS20200950A patent/RS60897B1/sr unknown
- 2011-04-15 MX MX2012012010A patent/MX340683B/es active IP Right Grant
- 2011-04-15 SG SG10202112020VA patent/SG10202112020VA/en unknown
- 2011-04-15 PT PT171634116T patent/PT3202789T/pt unknown
- 2011-04-15 BR BR112012026403-6A patent/BR112012026403B1/pt active IP Right Grant
- 2011-04-15 HU HUE11730120A patent/HUE035098T2/en unknown
- 2011-04-15 EP EP18205524.4A patent/EP3466977B1/en active Active
- 2011-04-15 CN CN2011800296749A patent/CN103038257A/zh active Pending
- 2011-04-15 DK DK17163411.6T patent/DK3202789T3/da active
- 2011-04-15 ES ES11730120.0T patent/ES2633105T3/es active Active
- 2011-04-15 PT PT117301200T patent/PT2558499T/pt unknown
- 2011-04-15 PL PL17163411T patent/PL3202789T3/pl unknown
- 2011-04-15 DK DK11730120.0T patent/DK2558499T3/en active
- 2011-04-15 HU HUE17163411A patent/HUE050858T2/hu unknown
- 2011-04-15 WO PCT/US2011/032641 patent/WO2011130603A2/en active Application Filing
- 2011-04-15 NZ NZ602676A patent/NZ602676A/en unknown
- 2011-04-15 ME MEP-2017-148A patent/ME02793B/me unknown
- 2011-04-15 LT LTEP17163411.6T patent/LT3202789T/lt unknown
- 2011-04-15 US US13/641,199 patent/US20140161794A1/en not_active Abandoned
- 2011-04-15 AU AU2011239512A patent/AU2011239512B2/en active Active
- 2011-04-15 KR KR1020127027585A patent/KR20130066584A/ko not_active Application Discontinuation
- 2011-04-15 PL PL18205524T patent/PL3466977T3/pl unknown
- 2011-04-15 EP EP11730120.0A patent/EP2558499B1/en active Active
- 2011-04-15 RS RS20170701A patent/RS56082B1/sr unknown
-
2017
- 2017-01-30 JP JP2017014410A patent/JP6525440B2/ja active Active
- 2017-07-10 CY CY20171100728T patent/CY1119154T1/el unknown
- 2017-07-10 HR HRP20171045TT patent/HRP20171045T1/hr unknown
- 2017-12-12 US US15/838,884 patent/US10335485B2/en active Active
-
2018
- 2018-05-15 JP JP2018093927A patent/JP2018123165A/ja not_active Withdrawn
-
2019
- 2019-06-14 US US16/441,974 patent/US11083791B2/en active Active
- 2019-10-09 JP JP2019185798A patent/JP2020019811A/ja active Pending
-
2020
- 2020-06-02 CY CY20201100516T patent/CY1122978T1/el unknown
- 2020-08-03 HR HRP20201219TT patent/HRP20201219T1/hr unknown
-
2021
- 2021-07-02 US US17/366,903 patent/US11571477B2/en active Active
-
2022
- 2022-07-22 JP JP2022117076A patent/JP2022141875A/ja active Pending
-
2023
- 2023-02-06 US US18/165,146 patent/US20240100155A1/en active Pending
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25I | Requirement for requested change of headquarter |
Owner name: BIOGEN IDEC MA INC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: BIOGEN MA INC. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: BIOGEN MA INC. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |